Sidestepping the "Washout," SV Life Sciences Closes $523 Million Fund
This article was originally published in The Pink Sheet Daily
Executive Summary
The dedicated health care fund says it will stick with its formula: half the fund into biopharma, the other half spread among devices, diagnostics, services, and information technology.
You may also be interested in...
Shrinking Funding Rounds For European Biotechs Are No Surprise, But Series A Rounds Look Healthy, If Few
Nearly half (48%) of the 27 fundraisings by private European biotech companies so far this year have been for sums totaling $10 million or less, according to Elsevier's "Strategic Transactions" database. That's a significant increase over the same period in 2010, when less than 30% of financings were sub-$10 million.
Shrinking Funding Rounds For European Biotechs Are No Surprise, But Series A Rounds Look Healthy, If Few
Nearly half (48%) of the 27 fundraisings by private European biotech companies so far this year have been for sums totaling $10 million or less, according to Elsevier's "Strategic Transactions" database. That's a significant increase over the same period in 2010, when less than 30% of financings were sub-$10 million.
Advent's Life Science Fund Attracts UK Government Backing
Advent Venture Partners Raises £70 million for new life sciences fund in Europe.